MiMedx Group, Inc. Board of Directors

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Mr. William F. Hulse IV

Mr. William F. Hulse IV

General Counsel & Chief Administrative Officer

Mr. Douglas C. Rice CPA

Mr. Douglas C. Rice CPA

Chief Financial Officer

Dr. David H. Mason Jr.

Dr. David H. Mason Jr.

Chief Medical Officer

Ms. Kate Surdez

Ms. Kate Surdez

Chief Human Resources Officer

Mr. Mark P. Graves

Mr. Mark P. Graves

Senior VP & Chief Compliance Officer

Ms. Hilary Dixon

Ms. Hilary Dixon

Vice President of Investor Relations & Corporate Strategic Communications

Mr. Scott M. Turner

Mr. Scott M. Turner

Senior Vice President of Operations & Procurement

Dr. Robert Benjamin Stein M.D., Ph.D.

Dr. Robert Benjamin Stein M.D., Ph.D.

President of Regenerative Medicine & Biologics Innovation

Mr. Matthew M. Notarianni

Mr. Matthew M. Notarianni

Head of Investor Relations

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.